MCID: CRB090
MIFTS: 45

Cerebral Hypoxia malady

Categories: Neuronal diseases

Aliases & Classifications for Cerebral Hypoxia

Aliases & Descriptions for Cerebral Hypoxia:

Name: Cerebral Hypoxia 51 52
Brain Hypoxia 69

Classifications:



Summaries for Cerebral Hypoxia

NINDS : 51 Cerebral hypoxia refers to a condition in which there is a decrease of oxygen supply to the brain even though there is adequate blood flow. Drowning, strangling, choking, suffocation, cardiac arrest, head trauma, carbon monoxide poisoning, and complications of general anesthesia can create conditions that can lead to cerebral hypoxia. Symptoms of mild cerebral hypoxia include inattentiveness, poor judgment, memory loss, and a decrease in motor coordination. Brain cells are extremely sensitive to oxygen deprivation and can begin to die within five minutes after oxygen supply has been cut off. When hypoxia lasts for longer periods of time, it can cause coma, seizures, and even brain death.  In brain death, there is no measurable activity in the brain, although cardiovascular function is preserved. Life support is required for respiration.

MalaCards based summary : Cerebral Hypoxia, also known as brain hypoxia, is related to hypoxia and anoxia. An important gene associated with Cerebral Hypoxia is FOS (Fos Proto-Oncogene, AP-1 Transcription Factor Subunit), and among its related pathways/superpathways are Signaling by GPCR and Innate Immune System. The drugs Dopamine and Levodopa have been mentioned in the context of this disorder. Affiliated tissues include brain, endothelial and monocytes, and related phenotypes are Decreased viability with paclitaxel and cellular

Wikipedia : 71 Cerebral hypoxia is a form of hypoxia (reduced supply of oxygen), specifically involving the brain; when... more...

Related Diseases for Cerebral Hypoxia

Diseases related to Cerebral Hypoxia via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 30)
id Related Disease Score Top Affiliating Genes
1 hypoxia 11.5
2 anoxia 11.4
3 brain ischemia 10.9
4 cerebritis 10.7
5 ischemia 10.5
6 neuronitis 10.1
7 brain injury 10.0
8 suppurative periapical periodontitis 9.9 CREB1 FOS IGF1
9 traumatic brain injury 9.8
10 hypotrichosis 8 9.8 CASP3 FOS IGF1
11 cardiac arrest 9.7
12 encephalopathy 9.6
13 cerebral artery occlusion 9.6
14 muscular dystrophy-dystroglycanopathy , type b, 2 9.5 CASP3 FOS IGF1 PTK2
15 dementia 9.5
16 endotheliitis 9.5
17 vascular disease 9.5
18 epilepsy 9.5
19 laryngitis 9.5
20 lactic acidosis 9.5
21 sudden infant death syndrome 9.5
22 dystonia 9.5
23 moyamoya disease 9.5
24 intracranial hypertension 9.5
25 wallerian degeneration 9.5
26 focal dystonia 9.5
27 myoclonus 9.5
28 pulmonary edema 9.5
29 syncope 9.5
30 dysautonomia 8.4 BCAR1 CAMK4 CASP3 CASP9 CREB1 FOS

Graphical network of the top 20 diseases related to Cerebral Hypoxia:



Diseases related to Cerebral Hypoxia

Symptoms & Phenotypes for Cerebral Hypoxia

GenomeRNAi Phenotypes related to Cerebral Hypoxia according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability with paclitaxel GR00179-A-1 8.92 CASP3 IGF1 PTK2
2 Decreased viability with paclitaxel GR00179-A-2 8.92 IGF1

MGI Mouse Phenotypes related to Cerebral Hypoxia:

44 (show all 18)
id Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.31 BCAR1 CASP9 CAMK4 CREB1 CASP3 IGF1
2 growth/size/body region MP:0005378 10.26 BCAR1 CASP9 CAMK4 CREB1 CASP3 IGF1
3 endocrine/exocrine gland MP:0005379 10.24 CASP9 CAMK4 CREB1 CASP3 IGF1 ITGB1
4 cardiovascular system MP:0005385 10.23 CREB1 CASP3 BCAR1 CASP9 IGF1 ITGB1
5 mortality/aging MP:0010768 10.17 CASP3 BCAR1 CASP9 CAMK4 CREB1 IGF1
6 hematopoietic system MP:0005397 10.16 CASP3 CASP9 CAMK4 IGF1 ITGB1 FOS
7 homeostasis/metabolism MP:0005376 10.15 CASP3 CAMK4 CREB1 IGF1 FOS ITGAV
8 immune system MP:0005387 10.13 CASP3 CASP9 CAMK4 IGF1 ITGB1 FOS
9 embryo MP:0005380 10.09 CREB1 BCAR1 CASP9 FOS ITGAV ITGB1
10 nervous system MP:0003631 10.02 CASP3 CASP9 CAMK4 CREB1 IGF1 ITGB1
11 muscle MP:0005369 10.01 BCAR1 CREB1 CASP3 IGF1 ITGB1 ITGAV
12 craniofacial MP:0005382 9.96 CASP3 CASP9 FOS ITGAV ITGB1
13 integument MP:0010771 9.93 CASP3 CAMK4 IGF1 FOS ITGB1 PTK2
14 normal MP:0002873 9.8 CREB1 CAMK4 IGF1 FOS NOS1 ITGB1
15 neoplasm MP:0002006 9.77 ITGAV IGF1 FOS ITGB1 PTK2
16 reproductive system MP:0005389 9.76 CREB1 CASP3 CAMK4 IGF1 ITGB1 FOS
17 respiratory system MP:0005388 9.5 CREB1 CASP3 CASP9 IGF1 ITGB1 PTK2
18 skeleton MP:0005390 9.17 CREB1 CASP3 CAMK4 IGF1 FOS NOS1

Drugs & Therapeutics for Cerebral Hypoxia

Drugs for Cerebral Hypoxia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 263)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dopamine Approved Phase 4,Phase 2,Phase 1 51-61-6, 62-31-7 681
2
Levodopa Approved Phase 4 59-92-7 6047
3
Epinephrine Approved, Vet_approved Phase 4,Phase 2,Phase 3 51-43-4 5816
4
Valproic Acid Approved, Investigational Phase 4 99-66-1 3121
5
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
6
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
7
Clonazepam Approved, Illicit Phase 4 1622-61-3 2802
8
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
9
Magnesium Sulfate Approved, Vet_approved Phase 4,Phase 3,Phase 2 7487-88-9 24083
10
Indomethacin Approved, Investigational Phase 4,Phase 1,Phase 2 53-86-1 3715
11
Memantine Approved, Investigational Phase 4 19982-08-2 4054
12
Acetazolamide Approved, Vet_approved Phase 4 59-66-5 1986
13
Remifentanil Approved Phase 4 132875-61-7 60815
14
Ketamine Approved, Vet_approved Phase 4 6740-88-1 3821
15
Methazolamide Approved Phase 4 554-57-4 4100
16
Heparin Approved, Investigational Phase 4 9005-49-6 772 46507594
17
Vitamin C Approved, Nutraceutical Phase 4,Phase 3,Phase 1 50-81-7 5785 54670067
18
Creatine Approved, Nutraceutical Phase 4 57-00-1 586
19
Vitamin E Approved, Nutraceutical, Vet_approved Phase 4,Phase 3 59-02-9 14985
20
Choline Approved, Nutraceutical Phase 4 62-49-7 305
21 Ether Phase 4
22 Analgesics Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
23 calcium channel blockers Phase 4,Phase 3,Phase 2
24 diuretics Phase 4,Phase 3,Phase 1,Phase 2
25 GABA Agents Phase 4,Phase 1
26 Natriuretic Agents Phase 4,Phase 3,Phase 1,Phase 2
27 GABA Modulators Phase 4,Phase 1
28 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
29 Cyclooxygenase Inhibitors Phase 4,Phase 2,Phase 1
30 Tocolytic Agents Phase 4,Phase 3,Phase 2,Phase 1
31 Nootropic Agents Phase 4,Phase 3,Phase 2
32 Analgesics, Non-Narcotic Phase 4,Phase 2,Phase 1,Early Phase 1
33 Tranquilizing Agents Phase 4
34 Anesthetics Phase 4,Phase 3,Phase 2,Phase 1
35 Dihydroxyphenylalanine Phase 4
36 Anesthetics, General Phase 4,Phase 1,Phase 2
37 Anesthetics, Inhalation Phase 4,Phase 1,Phase 2
38 Anesthetics, Intravenous Phase 4
39 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
40 Dopamine Agents Phase 4,Phase 2,Phase 1
41 Epinephryl borate Phase 4,Phase 2,Phase 3
42 Hypnotics and Sedatives Phase 4,Phase 1,Early Phase 1
43 Anti-Arrhythmia Agents Phase 4,Phase 3,Phase 2
44 Platelet Aggregation Inhibitors Phase 4
45 Anticonvulsants Phase 4,Phase 3,Phase 2,Phase 1
46 Protective Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
47 Anti-Inflammatory Agents Phase 4,Phase 2,Phase 3,Phase 1
48 Psychotropic Drugs Phase 4,Phase 3
49 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 2,Phase 1
50 Antimanic Agents Phase 4

Interventional clinical trials:

(show top 50) (show all 276)
id Name Status NCT ID Phase
1 Sevoflurane Decreases the Risk of Postoperative Delirium After Cerebral Hypoxemia During Surgery Unknown status NCT02133638 Phase 4
2 Sodium Bicarbonate in Cardiopulmonary Resuscitation Unknown status NCT01377337 Phase 4
3 Dopamine Treatment in Children With Cerebral Palsy With Dystonia- A Double Blind Controlled Study Unknown status NCT01361373 Phase 4
4 The Benefit of Prophylactic Anticonvulsant in Post Cardiac Arrest Syndrome With Induced Mild Hypothermia Unknown status NCT01083784 Phase 4
5 Single High Dose Vitamin C, E in Severe Birth Asphyxia Completed NCT01743742 Phase 4
6 AZ, MZ, and the Pulmonary System Response to Hypoxia Completed NCT02760121 Phase 4
7 5-hydroxytryptophan and Creatine for Treatment Resistant Depression Associated With Hypoxia in Females Completed NCT02356107 Phase 4
8 Neuroprotection by Magnesium Sulfate Given to Women at Risk of Very Preterm Birth Completed NCT00120588 Phase 4
9 Safety Study of Analgesia After Craniotomy Surgery With End Tidal (ET) Carbon Dioxide (CO2) Monitoring Completed NCT01327677 Phase 4
10 Propofol-Ketamine vs Remifentanyl-Ketamine for Sedation in Pediatric Patients Undergoing Colonoscopy Completed NCT02602743 Phase 4
11 Clinical and Economical Interest of Endovascular Cooling in the Management of Cardiac Arrest (ICEREA Study) Completed NCT00392639 Phase 4
12 Placebo-controlled Trial of 5-hydroxytryptophan and Creatine for SSRI or SNRI Augmentation in Treatment Resistant Depression in Females Recruiting NCT02922725 Phase 4
13 Citicoline Effect on Non-arteritic Anterior Ischemic Optic Neuropathy (NAION) Recruiting NCT03046693 Phase 4
14 Cerebral Blood Flow and PETCO2 on Neuromuscular Function During Environmental Stress Active, not recruiting NCT01830335 Phase 4
15 Changes of Gas Values in Cord Blood Versus Time and Temperature Not yet recruiting NCT02785367 Phase 4
16 Namenda to Prevent Post-Operative Delirium Terminated NCT00303433 Phase 4
17 Efficacy Study of Hypothermia Plus Magnesium Sulphate(MgSO4) in the Management of Term and Near Term Babies With Hypoxic Ischemic Encephalopathy Unknown status NCT01646619 Phase 3
18 Antenatal Allopurinol During Fetal Hypoxia Unknown status NCT00189007 Phase 3
19 Late Hypothermia for Hypoxic-Ischemic Encephalopathy Completed NCT00614744 Phase 2, Phase 3
20 Whole-Body Cooling for Birth Asphyxia in Term Infants Completed NCT00005772 Phase 3
21 Evaluation of SC-V Versus Conventional CPR Completed NCT00000502 Phase 3
22 Infant Heart Surgery: Central Nervous System Sequelae of Circulatory Arrest Completed NCT00000470 Phase 3
23 Safety and Efficacy of Hypothermia to Treat Neonatal Hypoxic-Ischemic Encephalopathy Completed NCT00890409 Phase 3
24 Neonatal Resuscitation in Zambia Completed NCT00097097 Phase 3
25 Hypothermia Enhanced by Magnesium Sulphate Completed NCT02499393 Phase 2, Phase 3
26 Anti-Oxidant Supplementation for the Prevention of Acute Mountain Sickness Completed NCT00664001 Phase 3
27 Piracetam for Treatment Tardive Dyskinesia Completed NCT00190008 Phase 3
28 Caffeine for Apnea of Prematurity (CAP) Completed NCT00182312 Phase 3
29 Multicenter Efficacy Study of Recombinant Human Erythropoietin in Acute Ischemic Stroke Completed NCT00604630 Phase 2, Phase 3
30 Early Lactate-Directed Therapy in the Intensive Care Unit (ICU) Completed NCT00270673 Phase 3
31 Assessment of Desogestrel in Ondine Syndrome Completed NCT01243697 Phase 2, Phase 3
32 Therapeutic Hypothermia to Improve Survival After Cardiac Arrest in Pediatric Patients-THAPCA-OH [Out of Hospital] Trial Completed NCT00878644 Phase 3
33 Therapeutic Hypothermia to Improve Survival After Cardiac Arrest in Pediatric Patients-THAPCA-IH [In Hospital] Trial Completed NCT00880087 Phase 3
34 Efficacy of Fluoxetine Against Seizure-induced Central Apneas Completed NCT02569970 Phase 3
35 Phase III Study of Hemospan® to Prevent Hypotension in Hip Arthroplasty Completed NCT00421200 Phase 3
36 Phase III Study of Hemospan® for Treating Hypotension in Hip Arthroplasty Completed NCT00420277 Phase 3
37 Preemie Hypothermia for Neonatal Encephalopathy Recruiting NCT01793129 Phase 2, Phase 3
38 Role of Citicoline in Treatment of Newborns With Hypoxic Ischemic Encephalopathy Recruiting NCT03181646 Phase 3
39 PAEAN - Erythropoietin for Hypoxic Ischaemic Encephalopathy in Newborns Recruiting NCT03079167 Phase 3
40 Hydrocortisone Treatment In Systemic Low Blood Pressure During Hypothermia in Asphyxiated Newborns Recruiting NCT02700828 Phase 2, Phase 3
41 High-dose Erythropoietin for Asphyxia and Encephalopathy Recruiting NCT02811263 Phase 3
42 Clinical Trial of Efficacy and Safety of Tenoten for Children Liquid Dosage Form in the Treatment of Sequelae of Perinatal Injury to Central Nervous System in Children Recruiting NCT03159611 Phase 3
43 Is Peri-operative Hyperoxemia a Risk Factor for Postoperative Complications? Recruiting NCT02562781 Phase 3
44 Efficacy of Erythropoietin to Improve Survival and Neurological Outcome in Hypoxic Ischemic Encephalopathy Active, not recruiting NCT01732146 Phase 3
45 Effect of Allopurinol for Hypoxic-ischemic Brain Injury on Neurocognitive Outcome Not yet recruiting NCT03162653 Phase 3
46 Erythropoietin in Management of Neonatal Hypoxic Ischemic Encephalopathy Not yet recruiting NCT03163589 Phase 3
47 Prevention of Epileptic Seizures in Acute intraCerebral Haemorrhage Not yet recruiting NCT02631759 Phase 3
48 Optimizing (Longer, Deeper) Cooling for Neonatal Hypoxic-Ischemic Encephalopathy(HIE) Terminated NCT01192776 Phase 3
49 Hypertonic Saline vs. Mannitol for Elevated Intercranial Pressure Terminated NCT01111682 Phase 3
50 Xenon and Cooling Therapy in Babies at High Risk of Brain Injury Following Poor Condition at Birth Unknown status NCT01545271 Phase 1, Phase 2

Search NIH Clinical Center for Cerebral Hypoxia

Genetic Tests for Cerebral Hypoxia

Anatomical Context for Cerebral Hypoxia

MalaCards organs/tissues related to Cerebral Hypoxia:

39
Brain, Endothelial, Monocytes, Cortex, Spleen, Lung

Publications for Cerebral Hypoxia

Articles related to Cerebral Hypoxia:

(show top 50) (show all 246)
id Title Authors Year
1
The SafeBoosC II randomized trial: treatment guided by near-infrared spectroscopy reduces cerebral hypoxia without changing early biomarkers of brain injury. ( 26679155 )
2016
2
Translational challenge models in support of efficacy studies: effect of cerebral hypoxia on cognitive performances in rodents. ( 27189464 )
2016
3
Does cerebral hypoxia facilitate central fatigue? ( 26891346 )
2016
4
Application of a novel rectal cooling device in hypothermia therapy after cerebral hypoxia-ischemia in rats. ( 27613331 )
2016
5
Simultaneous PET/MRI Imaging During Mouse Cerebral Hypoxia-ischemia. ( 26437227 )
2015
6
A Thrombotic Stroke Model Based On Transient Cerebral Hypoxia-ischemia. ( 26325524 )
2015
7
Neuronal death after perinatal cerebral hypoxia-ischemia: Focus on autophagy-mediated cell death. ( 26225751 )
2015
8
Poloxamer 188 Attenuates Cerebral Hypoxia/Ischemia Injury in Parallel with Preventing Mitochondrial Membrane Permeabilization and Autophagic Activation. ( 25966641 )
2015
9
Genetic deletion of neuronal pentraxin 1 expression prevents brain injury in a neonatal mouse model of cerebral hypoxia-ischemia. ( 25554688 )
2015
10
Prophylactic Subacute Administration of Zinc Increases CCL2, CCR2, FGF2, and IGF-1 Expression and Prevents the Long-Term Memory Loss in a Rat Model of Cerebral Hypoxia-Ischemia. ( 26355725 )
2015
11
Brain barrier properties and cerebral blood flow in neonatal mice exposed to cerebral hypoxia-ischemia. ( 25627141 )
2015
12
Catatonia After Cerebral Hypoxia: Do the Usual Treatments Apply? ( 25262046 )
2014
13
The impact of Ly6Clow monocytes after cerebral hypoxia-ischemia in adult mice. ( 24780898 )
2014
14
Cerebral hypoxia-ischemia causes cardiac damage in a rat model. ( 24840931 )
2014
15
Cerebral hypoxia immediately following delivery of very low birth weight infants. ( 24393297 )
2014
16
Cerebral hypoxia-ischemia increases toll-like receptor 2 and 4 expression in the hippocampus of neonatal rats. ( 25530127 )
2014
17
Evaluation of 2-[A^a8,F]fluoroacetate kinetics in rodent models of cerebral hypoxia-ischemia. ( 24517980 )
2014
18
A combination of mild hypothermia and sevoflurane affords long-term protection in a modified neonatal mouse model of cerebral hypoxia-ischemia. ( 24878681 )
2014
19
Simulating NIRS and MRS measurements during cerebral hypoxia-ischaemia in piglets using a computational model. ( 24729232 )
2014
20
Cerebral hypoxia, missing cortical somatosensory evoked potentials and recovery of consciousness. ( 24720818 )
2014
21
Therapeutic benefits of delayed lithium administration in the neonatal rat after cerebral hypoxia-ischemia. ( 25211332 )
2014
22
Cerebral hypoxia in a cat following pharyngoscopy involving use of a mouth gag. ( 22924887 )
2013
23
Targeted drug delivery to treat pain and cerebral hypoxia. ( 23343976 )
2013
24
Brain mitochondrial oxidative metabolism during and after cerebral hypoxia-ischemia studied by simultaneous phosphorus magnetic-resonance and broadband near-infrared spectroscopy. ( 23959202 )
2013
25
Erythropoietin: a neuroprotective agent in cerebral hypoxia, neurodegeneration, and epilepsy. ( 23530506 )
2013
26
Amiloride but not memantine reduces neurodegeneration, seizures and myoclonic jerks in rats with cardiac arrest-induced global cerebral hypoxia and reperfusion. ( 23593189 )
2013
27
Subacute zinc administration and L-NAME caused an increase of NO, zinc, lipoperoxidation, and caspase-3 during a cerebral hypoxia-ischemia process in the rat. ( 23997853 )
2013
28
Pathology of the right ventricle: a comparison between traumatic brain injury, afterload mismatch and cerebral hypoxia. ( 23375752 )
2013
29
Salvinorin A administration after global cerebral hypoxia/ischemia preserves cerebrovascular autoregulation via kappa opioid receptor in piglets. ( 22911847 )
2012
30
The increased activity of TRPV4 channel in the astrocytes of the adult rat hippocampus after cerebral hypoxia/ischemia. ( 22761937 )
2012
31
Dynamic FDG PET for assessing early effects of cerebral hypoxia and resuscitation in new-born pigs. ( 22297457 )
2012
32
Apoptosis-inducing factor downregulation increased neuronal progenitor, but not stem cell, survival in the neonatal hippocampus after cerebral hypoxia-ischemia. ( 22534064 )
2012
33
An angiogenic role for the I+5I^1 integrin in promoting endothelial cell proliferation during cerebral hypoxia. ( 22721769 )
2012
34
Use of serum biomarkers to predict cerebral hypoxia after severe traumatic brain injury. ( 22360297 )
2012
35
Cognitive decline in moyamoya: influence of chronic cerebral hypoxia, history of stroke, or comorbid conditions? ( 22171927 )
2012
36
Chronic cerebral hypoxia promotes arteriogenic remodeling events that can be identified by reduced endoglin (CD105) expression and a switch in I^1 integrins. ( 22739620 )
2012
37
Experimental evidence of the potential use of erythropoietin by intranasal administration as a neuroprotective agent in cerebral hypoxia. ( 21756166 )
2011
38
Whole body hypothermia broadens the therapeutic window of intranasally administered IGF-1 in a neonatal rat model of cerebral hypoxia-ischemia. ( 21316352 )
2011
39
Use of neuroimaging techniques to detect cerebral hypoxia in healthy aircrew. ( 21748916 )
2011
40
Tin protoporphyrin provides protection following cerebral hypoxia-ischemia: involvement of alternative pathways. ( 21538467 )
2011
41
Lateralized and sex-dependent behavioral and morphological effects of unilateral neonatal cerebral hypoxia-ischemia in the rat. ( 20156487 )
2010
42
PAI-1-derived peptide EEIIMD prevents impairment of cerebrovasodilation by augmenting p38 MAPK upregulation after cerebral hypoxia/ischemia. ( 20435843 )
2010
43
Nuclear translocation and calpain-dependent reduction of Bcl-2 after neonatal cerebral hypoxia-ischemia. ( 19782128 )
2010
44
NF-kappaB inhibition after neonatal cerebral hypoxia-ischemia improves long-term motor and cognitive outcome in rats. ( 20132887 )
2010
45
The PPAR-gamma agonist, darglitazone, restores acute inflammatory responses to cerebral hypoxia-ischemia in the diabetic ob/ob mouse. ( 19861974 )
2010
46
Neonatal cerebral hypoxia-ischemia impairs plasticity in rat visual cortex. ( 20053890 )
2010
47
Nitric oxide pros and cons: The role of L-arginine, a nitric oxide precursor, and idebenone, a coenzyme-Q analogue in ameliorating cerebral hypoxia in rat. ( 20637840 )
2010
48
Decompressive laparotomy to treat intractable cerebral hypoxia. ( 19088554 )
2009
49
Cerebral hypoxia-ischemia: focus on the use of magnetic resonance imaging and spectroscopy in research on animals. ( 19428791 )
2009
50
Docosahexaenoic acid pretreatment confers neuroprotection in a rat model of perinatal cerebral hypoxia-ischemia. ( 19254588 )
2009

Variations for Cerebral Hypoxia

Expression for Cerebral Hypoxia

Search GEO for disease gene expression data for Cerebral Hypoxia.

Pathways for Cerebral Hypoxia

Pathways related to Cerebral Hypoxia according to GeneCards Suite gene sharing:

(show top 50) (show all 95)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
14.09 BCAR1 CAMK4 CASP3 CASP9 CREB1 IGF1
2
Show member pathways
13.94 CAMK4 CASP3 CASP9 CREB1 FOS ITGAV
3
Show member pathways
13.77 CASP3 CASP9 CREB1 FOS IGF1 ITGAV
4
Show member pathways
13.77 BCAR1 CASP3 CASP9 CREB1 FOS IGF1
5
Show member pathways
13.64 BCAR1 CAMK4 CREB1 FOS IGF1 ITGAV
6
Show member pathways
13.34 BCAR1 CASP3 CREB1 FOS ITGAV ITGB1
7
Show member pathways
13.31 CASP3 CASP9 CREB1 FOS IGF1 ITGAV
8
Show member pathways
13.26 BCAR1 IGF1 ITGAV ITGB1 NOS1 PTK2
9
Show member pathways
12.97 CASP9 CREB1 FOS IGF1 PTK2
10
Show member pathways
12.96 BCAR1 CAMK4 CREB1 IGF1 ITGAV ITGB1
11
Show member pathways
12.95 FOS IGF1 ITGAV ITGB1 PTK2
12
Show member pathways
12.94 BCAR1 CAMK4 CASP3 FOS IGF1 PTK2
13
Show member pathways
12.87 BCAR1 FOS ITGAV ITGB1 NOS1 PTK2
14
Show member pathways
12.86 BCAR1 FOS IGF1 ITGB1 PTK2
15
Show member pathways
12.84 BCAR1 FOS IGF1 ITGAV ITGB1 PTK2
16
Show member pathways
12.77 CASP3 CASP9 FOS IGF1
17
Show member pathways
12.77 CAMK4 CREB1 FOS ITGAV ITGB1 PTK2
18
Show member pathways
12.74 CAMK4 CASP9 CREB1 IGF1 ITGAV ITGB1
19
Show member pathways
12.72 CAMK4 CREB1 FOS NOS1
20
Show member pathways
12.62 CAMK4 CASP3 CASP9 CREB1 FOS ITGAV
21
Show member pathways
12.6 BCAR1 ITGAV ITGB1 PTK2
22 12.59 BCAR1 ITGAV ITGB1 PTK2
23
Show member pathways
12.57 CASP9 FOS ITGB1 NOS1 PTK2
24
Show member pathways
12.54 BCAR1 CASP9 IGF1 PTK2
25
Show member pathways
12.53 CAMK4 CASP3 CASP9 FOS PTK2
26 12.51 CASP9 CREB1 IGF1 ITGAV ITGB1 PTK2
27
Show member pathways
12.5 CAMK4 CREB1 FOS NOS1
28 12.46 CASP3 CASP9 FOS IGF1 ITGAV ITGB1
29
Show member pathways
12.45 CASP3 CREB1 FOS ITGB1 PTK2
30
Show member pathways
12.44 BCAR1 CASP3 CASP9 CREB1 FOS ITGAV
31
Show member pathways
12.44 BCAR1 CASP3 CASP9 CREB1 FOS IGF1
32
Show member pathways
12.41 CASP3 CASP9 ITGAV ITGB1 PTK2
33
Show member pathways
12.37 CASP9 CREB1 FOS IGF1
34
Show member pathways
12.37 CASP9 CREB1 FOS ITGAV PTK2
35
Show member pathways
12.37 CAMK4 CASP3 CASP9 CREB1 FOS NOS1
36
Show member pathways
12.35 CASP3 CASP9 CREB1 IGF1
37
Show member pathways
12.34 BCAR1 CASP9 FOS PTK2
38
Show member pathways
12.25 CAMK4 CREB1 FOS
39 12.25 CASP3 IGF1 ITGAV ITGB1 PTK2
40
Show member pathways
12.25 BCAR1 CAMK4 CASP3 CASP9 CREB1 FOS
41
Show member pathways
12.24 CASP3 CASP9 FOS ITGB1
42
Show member pathways
12.22 CASP3 CASP9 FOS
43 12.19 CASP3 CASP9 CREB1
44
Show member pathways
12.19 ITGAV ITGB1 PTK2
45
Show member pathways
12.18 IGF1 ITGAV ITGB1
46 12.17 BCAR1 CREB1 FOS PTK2
47 12.12 CASP3 CASP9 CREB1
48
Show member pathways
12.11 CASP3 CASP9 CREB1
49 12.11 ITGAV ITGB1 NOS1
50 12.11 CAMK4 CASP3 CREB1 FOS

GO Terms for Cerebral Hypoxia

Cellular components related to Cerebral Hypoxia according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 lamellipodium GO:0030027 9.33 BCAR1 ITGB1 PTK2
2 integrin complex GO:0008305 9.26 ITGAV ITGB1
3 focal adhesion GO:0005925 9.26 BCAR1 ITGAV ITGB1 PTK2
4 alphav-beta3 integrin-IGF-1-IGF1R complex GO:0035867 8.62 IGF1 ITGAV

Biological processes related to Cerebral Hypoxia according to GeneCards Suite gene sharing:

(show all 27)
id Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 9.9 IGF1 ITGAV ITGB1 PTK2
2 positive regulation of transcription, DNA-templated GO:0045893 9.83 CAMK4 CREB1 FOS IGF1 NOS1
3 extracellular matrix organization GO:0030198 9.81 ITGAV ITGB1 PTK2
4 response to lipopolysaccharide GO:0032496 9.8 CASP3 CASP9 FOS
5 cell migration GO:0016477 9.8 BCAR1 ITGAV ITGB1
6 positive regulation of apoptotic process GO:0043065 9.8 CASP3 CASP9 CREB1 ITGB1
7 aging GO:0007568 9.79 CASP9 CREB1 FOS
8 response to hypoxia GO:0001666 9.78 CASP3 CREB1 NOS1
9 response to organic cyclic compound GO:0014070 9.74 CASP3 CASP9 FOS
10 vascular endothelial growth factor receptor signaling pathway GO:0048010 9.63 BCAR1 ITGAV PTK2
11 positive regulation of cell migration GO:0030335 9.62 BCAR1 IGF1 ITGAV PTK2
12 ERK1 and ERK2 cascade GO:0070371 9.61 IGF1 ITGAV
13 heterotypic cell-cell adhesion GO:0034113 9.59 ITGAV ITGB1
14 positive regulation of osteoclast differentiation GO:0045672 9.58 CREB1 FOS
15 platelet formation GO:0030220 9.58 CASP3 CASP9
16 cell-substrate adhesion GO:0031589 9.56 ITGAV ITGB1
17 cell adhesion mediated by integrin GO:0033627 9.55 ITGAV ITGB1
18 negative regulation of anoikis GO:2000811 9.54 ITGB1 PTK2
19 cellular response to hepatocyte growth factor stimulus GO:0035729 9.52 BCAR1 CREB1
20 neurotrophin TRK receptor signaling pathway GO:0048011 9.51 BCAR1 CASP3
21 activation of cysteine-type endopeptidase activity involved in apoptotic process by cytochrome c GO:0008635 9.48 CASP3 CASP9
22 execution phase of apoptosis GO:0097194 9.43 CASP3 CASP9 PTK2
23 response to cobalt ion GO:0032025 9.4 CASP3 CASP9
24 glial cell apoptotic process GO:0034349 9.37 CASP3 CASP9
25 extrinsic apoptotic signaling pathway in absence of ligand GO:0097192 9.33 CASP3 CASP9 ITGAV
26 transforming growth factor beta receptor signaling pathway GO:0007179 9.26 CREB1 FOS ITGB1 PTK2
27 integrin-mediated signaling pathway GO:0007229 8.92 BCAR1 ITGAV ITGB1 PTK2

Molecular functions related to Cerebral Hypoxia according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 coreceptor activity GO:0015026 9.37 ITGAV ITGB1
2 fibronectin binding GO:0001968 9.32 ITGAV ITGB1
3 transcriptional activator activity, RNA polymerase II transcription factor binding GO:0001190 9.26 CREB1 FOS
4 cysteine-type endopeptidase activity involved in execution phase of apoptosis GO:0097200 9.16 CASP3 CASP9
5 protease binding GO:0002020 9.13 CASP3 ITGAV ITGB1
6 C-X3-C chemokine binding GO:0019960 8.62 ITGAV ITGB1

Sources for Cerebral Hypoxia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....